- Home
- CNTY vs ESLA Comparison
CNTY vs ESLA Comparison
Compare CNTY & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTY | ESLA |
|---|---|---|
| Founded | 1992 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 30.7M |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNTY | ESLA |
|---|---|---|
| Price | $1.28 | $0.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 65.1K | 31.7K |
| Earning Date | 05-08-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.14 | $0.68 |
| 52 Week High | $2.85 | $3.15 |
Technical Indicators
Market Signals| Indicator | CNTY | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 56.22 | 39.42 |
| Support Level | $1.24 | $0.70 |
| Resistance Level | $1.35 | $1.35 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 60.00 | 30.02 |
Price Performance
Historical ComparisonAbout CNTY Century Casinos Inc.
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.